KURA Kura Oncology Inc.

Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results

Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 5, 2026, before the U.S. financial markets open. Kura’s management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the financial results and provide a corporate update.

The live webcast and archived replay of the event may be accessed on the Investors section of the Company’s website at .

About Kura Oncology

Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™, the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the and follow us on  and .

Kura Contact

Investors and Media:

Greg Mann

858-987-4046



EN
26/02/2026

Underlying

KURAKura Oncology Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kura Oncology Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.45
CMCSA Comcast Corpora...
AMN AMN Healthcare ... ... (+38)

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

CMCSA COMCAST CORPORATION CLASS A
AMN AMN HEALTHCARE SERVICES INC.
TMUS T-MOBILE US INC.
VKTX VIKING THERAPEUTICS
PG PROCTER & GAMBLE COMPANY
MKTX MARKETAXESS HOLDINGS INC.
MCS MARCUS CORPORATION
KURA KURA ONCOLOGY INC.
HUN HUNTSMAN CORPORATION
FFIV F5 NETWORKS INC.
EMN EASTMAN CHEMICAL COMPANY
EDIT EDITAS MEDICINE INC.
CALM CAL-MAINE FOODS INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AWR AMERICAN STATES WATER COMPANY
FF FUTUREFUEL CORP.
JW.A JOHN WILEY & SONS INC. CLASS A
ENPH ENPHASE ENERGY INC.
PRAA PRA GROUP INC.
MLR MILLER INDUSTRIES INC.
PMTS CPI CARD GROUP
RCKT ROCKET PHARMACEUTICALS
KDP KEURIG DR PEPPER INC.
TW TRADEWEB MARKETS INC. CLASS A
NET CLOUDFLARE INC CLASS A
CZR CAESARS ENTERTAINMENT INC
DYN DYNE THERAPEUTICS
RELY REMITLY GLOBAL INC
VTEX VTEX
PFHC PROFRAC HLDG CORP
CAVA CAVA GROUP INC
AESI NEW ATLAS HOLDCO INC
KEI KOLIBRI GLOBAL ENERGY INC
RNAC CARTESIAN THERAPEUTICS INC
NEXN NEXXEN INTERNATIONAL LTD
STRZ STARZ ENTERTAINMENT CORP
ATOM 21SHARES COSMOS ETP
GRND TIGA ACQUISITION CORP
15h 15h 1 EN
 PRESS RELEASE
Free
KURA Kura Oncology ...

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635...

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 44,700 shares of common stock to four (4) new employees under the Company’s 2023 Inducement O...

March 6, 2026 1 EN
Wedbush Research
  • Wedbush Research
W WAYFAIR INC.
SHOP SHOPIFY INC.
MELI MERCADOLIBRE INC.
KURA KURA ONCOLOGY INC.
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
ETSY ETSY INC.
EBAY EBAY INC.
NFLX NETFLIX INC.
CCRN CROSS COUNTRY HEALTHCARE INC.
WVE WAVE LIFE SCIENCES
CVNA CARVANA CO. CLASS A
AMZN AMAZON.COM INC.
BKNG BOOKING HOLDINGS INC.
CHWY CHEWY INC. CLASS A
STTK SHATTUCK LABS
KROS KEROS THERAPEUTICS
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
DAWN DAY ONE BIOPHARMACEUTICALS INC
XMTR XOMETRY
TNGX INC.
ELYM TANGO THERAPEUTICS
APP INC
TTD ELIEM THERAPEUTICS INC
CMPX APPLOVIN CORP
RGTI THE TRADE DESK
EWTX INC.
CART COMPASS THERAPEUTICS
TLX RIGETTI COMPUTING INC
BBOT EDGEWISE THERAPEUTICS INC
MAPLEBEAR INC.
TELIX PHARMACEUTICALS LIMITED
BRIDGEBIO ONCOLOGY THERAPEUTICS INC
03/06/26 March 6, 2026 1 EN
Geoffrey Von Der Ahe ... (+2)
  • Geoffrey Von Der Ahe
  • Robert Driscoll
KURA KURA ONCOLOGY INC.
03/05/26 March 5, 2026 1 EN
 PRESS RELEASE
Free
KURA Kura Oncology ...

Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Resu...

Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results – KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, supporting ongoing development plans targeting up to 50% of AML patients – – Orange Book listing of patents extending up to 2044 reinforces long-term value for KOMZIFTI – – FIT-001 Phase 1b dose expansion initiated for darlifarnib and cabozantinib combination in advanced renal cell carcinoma – – Multiple 2026 clinical...

March 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch